What are the indications for blood transfusion in neonates and children?

Blood Transfusion Indications in Neonates and Children

For very preterm neonates (<30 weeks gestational age), use a restrictive red blood cell transfusion strategy with hemoglobin thresholds stratified by postnatal age and respiratory support requirements 1.

Specific Transfusion Thresholds for Very Preterm Neonates (<30 weeks GA)

The most recent high-quality evidence from 2024 establishes clear hemoglobin-based thresholds 1:

For Neonates on Respiratory Support

(invasive ventilation, CPAP, NIPPV, or nasal cannula ≥1 L/min)

• Postnatal week 1: Transfuse at Hb <11 g/dL (Hct <33%)
• Postnatal week 2: Transfuse at Hb <10 g/dL (Hct <30%)
• Postnatal week ≥3: Transfuse at Hb <9 g/dL (Hct <27%)

For Neonates on No or Minimal Respiratory Support

• Postnatal week 1: Transfuse at Hb <10 g/dL (Hct <30%)
• Postnatal week 2: Transfuse at Hb <8.5 g/dL (Hct <25%)
• Postnatal week ≥3: Transfuse at Hb <7 g/dL (Hct <21%)

This restrictive strategy is supported by moderate-certainty evidence from 6 RCTs involving 3,483 preterm neonates, showing no significant differences in mortality, neurodevelopmental impairment, or major morbidities (BPD, severe IVH, NEC, severe ROP) between restrictive and liberal transfusion strategies 1.

Critical Exceptions Requiring Higher Thresholds

Consider higher transfusion thresholds in these clinical scenarios 1:

• Acute decompensation or active bleeding
• Sepsis or necrotizing enterocolitis
• Requiring vasopressor or inotropic support
• Previous intrauterine or postnatal exchange transfusion
• Neonates receiving erythropoiesis-stimulating agents (guidelines do not apply)

Transfusion Indications for Term and Late Preterm Neonates

For hemodynamically unstable or acutely hypoxemic late preterm and term neonates, transfusion strategies must be individualized based on clinical condition 2. Key clinical indicators for transfusion include 3, 4:

• Acute hemorrhagic shock: Loss of ≥10% blood volume within 72 hours with anticipated further blood loss
• Severe symptomatic anemia with:
  • Tachypnea and tachycardia
  • Recurrent apnea and bradycardia
  • Poor feeding or failure to gain weight
  • Oxygen desaturation despite supplementation
• Cardiorespiratory disease: Hb <130 g/L when increased oxygen-carrying capacity is required
• Symptomatic anemia: Hb <80-100 g/L with clinical signs

Primary Indications Across All Neonates

The fundamental purpose of neonatal RBC transfusion is to prevent or treat tissue hypoxia from reduced oxygen delivery 5. Transfusions may also be given electively based on hemoglobin/hematocrit values without physiological changes, particularly when cardiopulmonary support requirements are high 5.

Special Considerations for Neonatal Transfusion Practice

Unique Physiological Factors 5

• Immunologic immaturity: Trans-placental maternal antibodies create different compatibility profiles
• Organ system immaturity: Increased susceptibility to infectious, metabolic, and immune complications
• Hemodynamic vulnerability: Limited capacity to accommodate rapid blood volume increases
• Disproportionate volumes: Neonates receive blood products disproportionate to their size relative to growth rate

Higher Risk Profile

Neonates face 3-fold higher adverse reaction rates compared to adults (37 vs 13 per 100,000 RBC units) 5. Specific concerns include associations with intraventricular hemorrhage, bronchopulmonary dysplasia, retinopathy of prematurity, and necrotizing enterocolitis 5.

Platelet Transfusion Thresholds

For stable preterm infants without fetal intracranial hemorrhage or major active bleeding, use a platelet transfusion threshold of <25 × 10⁹/L 2. This represents a shift toward more restrictive practice using lower safe thresholds between 20-30 × 10⁹/L 4.

Blood Loss Prevention Strategies

Minimize transfusion need through 2:

• Delayed cord clamping for ≥60 seconds in both preterm and term infants
• Using umbilical cord blood for initial laboratory work in preterm infants when feasible
• Avoiding routine blood work whenever possible
• Recognizing that weekly phlebotomy losses can reach 10-30% of total blood volume (10-25 mL/kg) in ELBW infants during the first two weeks 5

Common Pitfalls to Avoid

• Do not use hemoglobin/hematocrit alone as transfusion indication without clinical criteria unless meeting specific threshold-based protocols 6
• Do not apply these thresholds to neonates receiving erythropoiesis-stimulating agents 1
• Recognize patient identification risks unique to neonates who may lack names, share birth dates, and cannot self-identify 5
• Balance benefits against complications given the complex risk-benefit profile in this vulnerable population 5